NASDAQ:CPIX

Cumberland Pharmaceuticals Competitors

$2.99
-0.05 (-1.64 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.99
Now: $2.99
$3.02
50-Day Range
$3.01
MA: $3.21
$3.42
52-Week Range
$2.77
Now: $2.99
$4.14
Volume8,500 shs
Average Volume62,925 shs
Market Capitalization$44.61 million
P/E RatioN/A
Dividend YieldN/A
Beta0.32

Competitors

Cumberland Pharmaceuticals (NASDAQ:CPIX) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying CPIX stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Cumberland Pharmaceuticals, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Cumberland Pharmaceuticals and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cumberland Pharmaceuticals-8.36%3.86%1.92%
Johnson & Johnson21.01%34.64%13.40%

Risk & Volatility

Cumberland Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cumberland Pharmaceuticals and Johnson & Johnson's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$47.53 million0.94$-3,540,000.00$0.2313.00
Johnson & Johnson$82.06 billion5.21$15.12 billion$8.6818.69

Johnson & Johnson has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Cumberland Pharmaceuticals and Johnson & Johnson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cumberland Pharmaceuticals00103.00
Johnson & Johnson031102.79

Johnson & Johnson has a consensus target price of $182.6154, suggesting a potential upside of 12.56%. Given Johnson & Johnson's higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Cumberland Pharmaceuticals.

Institutional & Insider Ownership

26.2% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 39.7% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Cumberland Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Pfizer (NYSE:PFE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Cumberland Pharmaceuticals and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cumberland Pharmaceuticals-8.36%3.86%1.92%
Pfizer17.85%24.88%9.32%

Risk & Volatility

Cumberland Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cumberland Pharmaceuticals and Pfizer's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$47.53 million0.94$-3,540,000.00$0.2313.00
Pfizer$51.75 billion4.16$16.27 billion$2.9513.07

Pfizer has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Cumberland Pharmaceuticals and Pfizer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cumberland Pharmaceuticals00103.00
Pfizer010302.23

Pfizer has a consensus target price of $38.5714, suggesting a potential upside of 0.00%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Cumberland Pharmaceuticals.

Institutional & Insider Ownership

26.2% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 39.7% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Pfizer beats Cumberland Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Cumberland Pharmaceuticals and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cumberland Pharmaceuticals-8.36%3.86%1.92%
Merck & Co., Inc.24.33%53.83%16.83%

Risk & Volatility

Cumberland Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cumberland Pharmaceuticals and Merck & Co., Inc.'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$47.53 million0.94$-3,540,000.00$0.2313.00
Merck & Co., Inc.$46.84 billion4.19$9.84 billion$5.1914.93

Merck & Co., Inc. has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Cumberland Pharmaceuticals and Merck & Co., Inc., as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cumberland Pharmaceuticals00103.00
Merck & Co., Inc.021102.85

Merck & Co., Inc. has a consensus target price of $96.2727, suggesting a potential upside of 24.27%. Given Merck & Co., Inc.'s higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Cumberland Pharmaceuticals.

Institutional & Insider Ownership

26.2% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 39.7% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Cumberland Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Cumberland Pharmaceuticals (NASDAQ:CPIX) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Risk & Volatility

Cumberland Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Profitability

This table compares Cumberland Pharmaceuticals and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cumberland Pharmaceuticals-8.36%3.86%1.92%
AbbVie18.16%439.24%13.22%

Valuation & Earnings

This table compares Cumberland Pharmaceuticals and AbbVie's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$47.53 million0.94$-3,540,000.00$0.2313.00
AbbVie$33.27 billion5.72$7.88 billion$8.9412.07

AbbVie has higher revenue and earnings than Cumberland Pharmaceuticals. AbbVie is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

26.2% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 39.7% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Cumberland Pharmaceuticals and AbbVie, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cumberland Pharmaceuticals00103.00
AbbVie121302.75

AbbVie has a consensus target price of $115.75, suggesting a potential upside of 7.27%. Given AbbVie's higher probable upside, analysts clearly believe AbbVie is more favorable than Cumberland Pharmaceuticals.

Summary

AbbVie beats Cumberland Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Risk & Volatility

Cumberland Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Profitability

This table compares Cumberland Pharmaceuticals and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cumberland Pharmaceuticals-8.36%3.86%1.92%
Eli Lilly and24.01%166.45%15.18%

Earnings and Valuation

This table compares Cumberland Pharmaceuticals and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$47.53 million0.94$-3,540,000.00$0.2313.00
Eli Lilly and$22.32 billion8.13$8.32 billion$6.0431.33

Eli Lilly and has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

26.2% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 39.7% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cumberland Pharmaceuticals and Eli Lilly and, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cumberland Pharmaceuticals00103.00
Eli Lilly and041102.73

Eli Lilly and has a consensus target price of $196.40, suggesting a potential upside of 3.78%. Given Eli Lilly and's higher probable upside, analysts plainly believe Eli Lilly and is more favorable than Cumberland Pharmaceuticals.

Summary

Eli Lilly and beats Cumberland Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Risk & Volatility

Cumberland Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Profitability

This table compares Cumberland Pharmaceuticals and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cumberland Pharmaceuticals-8.36%3.86%1.92%
Bristol-Myers Squibb-0.11%27.48%10.77%

Earnings and Valuation

This table compares Cumberland Pharmaceuticals and Bristol-Myers Squibb's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$47.53 million0.94$-3,540,000.00$0.2313.00
Bristol-Myers Squibb$26.15 billion5.59$3.44 billion$4.6913.96

Bristol-Myers Squibb has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

26.2% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are held by institutional investors. 39.7% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cumberland Pharmaceuticals and Bristol-Myers Squibb, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cumberland Pharmaceuticals00103.00
Bristol-Myers Squibb021312.94

Bristol-Myers Squibb has a consensus target price of $74.60, suggesting a potential upside of 13.96%. Given Bristol-Myers Squibb's higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Cumberland Pharmaceuticals.

Summary

Bristol-Myers Squibb beats Cumberland Pharmaceuticals on 12 of the 15 factors compared between the two stocks.


Cumberland Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$162.24-1.1%$427.13 billion$82.06 billion25.51Upcoming Earnings
News Coverage
Pfizer logo
PFE
Pfizer
2.3$38.57-2.5%$215.13 billion$51.75 billion24.88Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$77.47-1.0%$196.03 billion$46.84 billion17.14Increase in Short Interest
Analyst Revision
News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.91-0.9%$190.44 billion$33.27 billion22.81Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$189.25-1.8%$181.49 billion$22.32 billion30.92Analyst Revision
News Coverage
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$65.46-1.6%$146.23 billion$26.15 billion-595.04Analyst Upgrade
Decrease in Short Interest
Analyst Revision
Zoetis logo
ZTS
Zoetis
2.2$167.63-1.3%$79.62 billion$6.26 billion49.74Increase in Short Interest
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.87-0.5%$25.42 billionN/A0.00Dividend Announcement
Insider Selling
Increase in Short Interest
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.27-0.3%$20.90 billion$1.30 billion25.48Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.90-0.3%$9.51 billion$2.16 billion53.28Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62-1.1%$5.56 billion$4.84 billion-693.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.76-0.8%$2.67 billion$306.49 million25.57
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.01-1.4%$375.61 million$16.54 million-3.26News Coverage
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.42-1.5%$344.95 million$111.39 million24.43News Coverage
Lannett logo
LCI
Lannett
2.0$4.76-0.2%$197.07 million$545.74 million-6.61
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.28-1.2%$171.45 million$15.96 million-2.59
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.